Top

Drugs & Aging

Published in:

01-01-2018 | Systematic Review

Tools for Assessment of the Appropriateness of Prescribing and Association with Patient-Related Outcomes: A Systematic Review

Authors: Nashwa Masnoon, Sepehr Shakib, Lisa Kalisch-Ellett, Gillian E. Caughey

Published in: Drugs & Aging | Issue 1/2018

Abstract

Background

There are tools and criteria in the literature aimed at distinguishing between appropriate and inappropriate medicines use. However, many have not been externally validated with regard to patient-related outcomes, potentially limiting their use in clinical practice.

Objectives

The aim of the study was to conduct a systematic review to summarise (1) available prescribing appropriateness assessment tools and criteria, and (2) their associations with patient-related outcomes (external validity).

Methods

A systematic review was conducted using MEDLINE, EMBASE and Informit (Health Collection) databases to screen for articles in English that examined (1) tools to assess the appropriateness of prescribing and (2) associations of tools with patient-related outcomes, published between 2000 and 2016, without any limits placed on the study design, participant age or setting.

Results

After screening 1710 articles, removing duplicates and shortlisting relevant articles, 42 prescribing assessment tools were identified. Out of the 42 tools, 78.6% (n = 33) provided guidance around stopping inappropriate medications, 28.6% (n = 12) around starting appropriate medications, 61.9% (n = 26) were explicit (criteria based) and 31.0% (n = 13) had been externally validated, with hospitalisation being the most commonly used patient-related outcome (n = 9, 21.4%).

Conclusion

The results of this systematic review highlight the need for evidence-based and externally validated tools, which combine the different aspects of medication management to optimise patient-related outcomes. PROSPERO registration number: CRD42017067233.

Available only for authorised users

Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013. https://doi.org/10.1093/epirev/mxs009.PubMed

Roughead EE, Vitry AI, Caughey GE, et al. Multimorbidity, care complexity and prescribing for the elderly. Aging Health. 2011;7(5):695–705. https://doi.org/10.2217/ahe.11.64.CrossRef

Caughey GE, Ramsay EN, Vitry AI, et al. Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study. J Epidemiol Community Health. 2010;64(12):1036–42. https://doi.org/10.1136/jech.2009.088260.PubMedCrossRef

Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Aging Res Rev. 2011;10(4):430–9. https://doi.org/10.1016/j.arr.2011.03.003.CrossRef

Vitry AI, Zhang Y. Quality of Australian clinical guidelines and relevance to the care of older people with multiple comorbid conditions. Med J Aust. 2008;189(7):360–5.PubMed

Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294(6):716–24. https://doi.org/10.1001/jama.294.6.716.PubMedCrossRef

Milton JC, Hill-Smith I, Jackson SHD. Prescribing for older people. BMJ. 2008;336(7644):606–9. https://doi.org/10.1136/bmj.39503.424653.80.PubMedPubMedCentralCrossRef

Caughey GE, Roughead EE, Pratt N, et al. Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing? Pharmacoepidemiol Drug Saf. 2010;19(9):977–82. https://doi.org/10.1002/pds.2009.PubMedCrossRef

Caughey GE, Roughead EE, Vitry AI, et al. Comorbidity in the elderly with diabetes: identification of areas of potential treatment conflicts. Diabetes Res Clin Pract. 2010;87(3):385–93. https://doi.org/10.1016/j.diabres.2009.10.019.PubMedCrossRef

10.

Fried TR, O’Leary J, Towle V, et al. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc. 2014;62(12):2261–72. https://doi.org/10.1111/jgs.13153.PubMedPubMedCentralCrossRef

11.

Bushardt RL, Massey EB, Simpson TW, et al. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3(2):383–9.PubMedPubMedCentralCrossRef

12.

Shimizu K, Ishii S, Tanaka T, et al. Use of potentially inappropriate medication and polypharmacy in community-dwelling Japanese elderly population from the Kashiwa study. J Am Geriatr Soc. 2014;62:S249–50. https://doi.org/10.1111/jgs.12870.

13.

Sato I, Akazawa M. Polypharmacy and adverse drug reactions in Japanese elderly taking antihypertensives: a retrospective database study. Drug Healthc Patient Saf. 2013;5(1):143–50. https://doi.org/10.2147/DHPS.S45347.PubMedPubMedCentral

14.

Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Epidemiol Community Health. 2012;65(9):989–95. https://doi.org/10.1016/j.jclinepi.2012.02.018.

15.

Fulton MM, Riley Allen E. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract. 2005;17(4):123–32. https://doi.org/10.1111/j.1041-2972.2005.0020.x.PubMedCrossRef

16.

Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. https://doi.org/10.1186/s12877-017-0621-2.PubMedPubMedCentralCrossRef

17.

Pollock M, Bazaldua OV, Dobbie AE. Appropriate prescribing of medications: an eight-step approach. Am Fam Physician. 2007;75(2):231–6.PubMed

18.

NPS MEDICINEWISE. Identifying inappropriate prescribing. In: Older people & medicines. 2013. http://www.nps.org.au/topics/ages-life-stages/for-individuals/older-people-and-medicines/for-health-professionals/inappropriate-prescribing. Accessed 15 March 2017.

19.

Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781–7. https://doi.org/10.1001/archinte.167.8.781.PubMedCrossRef

20.

Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508–13. https://doi.org/10.1001/archinternmed.2007.106.PubMedCrossRef

21.

Carnahan RM, Lund BC, Perry PJ, et al. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481–6. https://doi.org/10.1177/0091270006292126.PubMedCrossRef

22.

American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46. https://doi.org/10.1111/jgs.13702.CrossRef

23.

Gallagher P, Ryan C, Byrne S, et al. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.PubMedCrossRef

24.

Kouladjian L, Gnjidic D, Chen TF, et al. Drug burden index in older adults: theoretical and practical issues. Clin Interv Aging. 2014;9:1503–15. https://doi.org/10.2147/CIA.S66660.PubMedPubMedCentralCrossRef

25.

Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097.PubMedPubMedCentralCrossRef

26.

CASP UK. CASP Checklists. In: Critical Appraisal Skills Programme (CASP) Making sense of evidence. CASP UK. 2017. https://www.casp-uk.net/casp-tools-checklists. Accessed 10 May 2017.

27.

Holmes HM, Sachs GA, Shega JW, et al. Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use. J Am Geriatr Soc. 2008;56(7):1306–11. https://doi.org/10.1111/j.1532-5415.2008.01741.x.PubMedCrossRef

28.

Tommelein E, Petrovic M, Somers A, et al. Older patients’ prescriptions screening in the community pharmacy: development of the Ghent Older People’s Prescriptions community Pharmacy Screening (GheOP³S) tool. J Public Health (Oxf). 2016;38(2):e158–70. https://doi.org/10.1093/pubmed/fdv090.CrossRef

29.

Berdot S, Bertrand M, Dartigues J-F, et al. Inappropriate medication use and risk of falls—a prospective study in a large community-dwelling elderly cohort. BMC Geriatr. 2009;9:30. https://doi.org/10.1186/1471-2318-9-30.PubMedPubMedCentralCrossRef

30.

Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA. 2001;286(22):2823–9.PubMedCrossRef

31.

Winit-Watjana W, Sakulrat P, Kespichayawattana J. Criteria for high-risk medication use in Thai older patients. Arch Gerontol Geriatr. 2008;47(1):35–51. https://doi.org/10.1016/j.archger.2007.06.006.PubMedCrossRef

32.

Niehoff KM, Rajeevan N, Charpentier PA, et al. Development of the tool to reduce inappropriate medications (TRIM): a clinical decision support system to improve medication prescribing for older adults. Pharmacotherapy. 2016;36(6):694–701. https://doi.org/10.1002/phar.1751.PubMedPubMedCentralCrossRef

33.

Rancourt C, Moisan J, Baillargeon L, et al. Potentially inappropriate prescriptions for older patients in long-term care. BMC Geriatr. 2004;4:9. https://doi.org/10.1186/1471-2318-4-9.PubMedPubMedCentralCrossRef

34.

PrescQIPP. Optimising safe and appropriate medicines use. 2017. https://www.prescqipp.info/projects/optimising-safe-and-appropriate-medicines-use. Accessed 2 Nov 2017.

35.

Nyborg G, Straand J, Klovning A, et al. The Norwegian General Practice-Nursing Home criteria (NORGEP-NH) for potentially inappropriate medication use: a web-based Delphi study. Scand J Primary Health Care. 2015;33(2):134–41. https://doi.org/10.3109/02813432.2015.1041833.CrossRef

36.

Mimica Matanovic S, Vlahovic-Palcevski V. Potentially inappropriate medications in the elderly: a comprehensive protocol. Eur J Clin Pharmacol. 2012;68(8):1123–38. https://doi.org/10.1007/s00228-012-1238-1.PubMedCrossRef

37.

Kojima T, Mizukami K, Tomita N, et al. Screening tool for older persons’ appropriate prescriptions for Japanese: Report of the Japan Geriatrics Society Working Group on “Guidelines for Medical Treatment and its Safety in the Elderly”. Geriatr Gerontol Int. 2016;16(9):983–1001. https://doi.org/10.1111/ggi.12890.PubMedCrossRef

38.

Maio V, Del Canale S, Abouzaid S. Using explicit criteria to evaluate the quality of prescribing in elderly Italian outpatients: a cohort study. J Clin Pharm Ther. 2010;35(2):219–29. https://doi.org/10.1111/j.1365-537(2710).2009.01094.x.PubMedCrossRef

39.

Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM List: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861–75. https://doi.org/10.1007/s00228-015-1860-9.PubMedPubMedCentralCrossRef

40.

Ruths S, Straand J, Nygaard HA. Multidisciplinary medication review in nursing home residents: what are the most significant drug-related problems? The Bergen District Nursing Home (BEDNURS) study. Qual Saf Health Care. 2003;12(3):176–80.PubMedPubMedCentralCrossRef

41.

Mann E, Bohmdorfer B, Fruhwald T, et al. Potentially inappropriate medication in geriatric patients: the Austrian Consensus Panel List. Wien Klin Wochenschr. 2012;124(5–6):160–9. https://doi.org/10.1007/s00508-011-0061-5.PubMedCrossRef

42.

Hassan NB, Ismail HC, Naing L, et al. Development and validation of a new prescription quality index. Br J Clin Pharmacol. 2010;70(4):500–13. https://doi.org/10.1111/j.1365-2125.2009.03597.x.PubMedPubMedCentralCrossRef

43.

Lewis T. Using the NO TEARS tool for medication review. BMJ. 2004;329(7463):434. https://doi.org/10.1136/bmj.329.7463.434.PubMedPubMedCentralCrossRef

44.

Basger BJ, Chen TF, Moles RJ. Validation of prescribing appropriateness criteria for older Australians using the RAND/UCLA appropriateness method. BMJ Open. 2012. https://doi.org/10.1136/bmjopen-2012-001431.PubMedPubMedCentral

45.

Drenth-van Maanen AC, van Marum RJ, Knol W, et al. Prescribing optimization method for improving prescribing in elderly patients receiving polypharmacy: results of application to case histories by general practitioners. Drugs Aging. 2009;26(8):687–701. https://doi.org/10.2165/11316400-000000000-00000.PubMedCrossRef

46.

Roth MT, Ivey JL, Esserman DA, et al. Individualized medication assessment and planning: optimizing medication use in older adults in the primary care setting. Pharmacotherapy. 2013;33(8):787–97. https://doi.org/10.1002/phar.1274.PubMedCrossRef

47.

Haque RM. ARMOR: a tool to evaluate polypharmacy in elderly persons. Ann Long-Term Care. 2009;17(6):26–30.

48.

Lee SS, Schwemm AK, Reist J, et al. Pharmacists’ and pharmacy students’ ability to identify drug-related problems using TIMER (Tool to Improve Medications in the Elderly via Review). Am J Pharmaceut Educ. 2009;73(3):52.CrossRef

49.

McLeod PJ, Huang AR, Tamblyn RM, et al. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ. 1997;156(3):385–91.PubMedPubMedCentral

50.

National Committee for Quality Assurance. HEDIS 2016. 2016.

51.

Van der Linden L, Decoutere L, Flamaing J, et al. Development and validation of the RASP list (Rationalization of Home Medication by an Adjusted STOPP list in Older Patients): a novel tool in the management of geriatric polypharmacy. Eur Geriatr Med. 2014;5(3):175–80. https://doi.org/10.1016/j.eurger.2013.12.005.CrossRef

52.

Laroche ML, Charmes JP, Merle L. Potentially inappropriate medications in the elderly: a French consensus panel list. Eur J Clin Pharmacol. 2007;63(8):725–31. https://doi.org/10.1007/s00228-007-0324-2.PubMedCrossRef

53.

Wenger NS, Roth CP, Shekelle P. Introduction to the assessing care of vulnerable elders-3 quality indicator measurement set. J Am Geriatr Soc. 2007;55(Suppl 2):S247–52. https://doi.org/10.1111/j.1532-5415.2007.01328.x.PubMedCrossRef

54.

Naugler CT, Brymer C, Stolee P, et al. Development and validation of an improving prescribing in the elderly tool. Can J Clin Pharmacol. 2000;7(2):103–7.PubMed

55.

Kuhn-Thiel AM, Weiss C, Wehling M. Consensus validation of the FORTA (Fit fOR The Aged) list: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014;31(2):131–40. https://doi.org/10.1007/s40266-013-0146-0.PubMedCrossRef

56.

Holt S, Schmiedl S, Thürmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Deutsches Ärzteblatt Int. 2010;107(31–32):543–51. https://doi.org/10.3238/arztebl.2010.0543.

57.

Chang CB, Yang SY, Lai HY, et al. Using published criteria to develop a list of potentially inappropriate medications for elderly patients in Taiwan. Pharmacoepidemiol Drug Saf. 2012;21(12):1269–79. https://doi.org/10.1002/pds.3274.PubMedCrossRef

58.

Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–51.PubMedCrossRef

59.

George J, Phun YT, Bailey MJ, et al. Development and validation of the Medication Regimen Complexity Index. Ann Pharmacother. 2004;38(9):1369–76. https://doi.org/10.1345/aph.1D479.PubMedCrossRef

60.

Linjakumpu T, Hartikainen S, Klaukka T, et al. A model to classify the sedative load of drugs. Int J Geriatr Psychiatry. 2003;18(6):542–4. https://doi.org/10.1002/gps.846.PubMedCrossRef

61.

Boustani M, Campbell N, Munger S, et al. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311–20. https://doi.org/10.2217/1745509X.4.3.311.CrossRef

62.

Evans DC, Gerlach AT, Christy JM, et al. Pre-injury polypharmacy as a predictor of outcomes in trauma patients. Int J Crit Illn Inj Sci. 2011;1(2):104–9. https://doi.org/10.4103/2229-5151.84793.PubMedPubMedCentralCrossRef

63.

Gnjidic D, Le Couteur DG, Abernethy DR, et al. Drug burden index and Beers criteria: impact on functional outcomes in older people living in self-care retirement villages. J Clin Pharmacol. 2012;52(2):258–65. https://doi.org/10.1177/0091270010395591.PubMedCrossRef

64.

Wehling M, Burkhardt H, Kuhn-Thiel A, et al. VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing. 2016;45(2):262–7. https://doi.org/10.1093/ageing/afv200.PubMedCrossRef

65.

Pugh MJ, Marcum ZA, Copeland LA, et al. The quality of quality measures: HEDIS^® quality measures for medication management in the elderly and outcomes associated with new exposure. Drugs Aging. 2013;30(8):645–54. https://doi.org/10.1007/s40266-013-0086-8.PubMedPubMedCentralCrossRef

66.

Henschel F, Redaelli M, Siegel M, et al. Correlation of incident potentially inappropriate medication prescriptions and hospitalization: an analysis based on the PRISCUS list. Drugs Real World Outcomes. 2015;2(3):249–59. https://doi.org/10.1007/s40801-015-0035-4.PubMedPubMedCentralCrossRef

67.

Frankenthal D, Lerman Y, Kalendaryev E, et al. Intervention with the screening tool of older persons potentially inappropriate Prescriptions/Screening Tool to Alert doctors to Right Treatment criteria in elderly residents of a chronic geriatric facility: a randomized clinical trial. J Am Geriatr Soc. 2014;62(9):1658–65. https://doi.org/10.1111/jgs.12993.PubMedCrossRef

68.

Moriarty F, Bennett K, Cahir C, et al. Potentially inappropriate prescribing according to STOPP and START and adverse outcomes in community-dwelling older people: a prospective cohort study. Br J Clin Pharmacol. 2016;82(3):849–57. https://doi.org/10.1111/bcp.12995.PubMedPubMedCentralCrossRef

69.

Gosch M, Wortz M, Nicholas JA, et al. Inappropriate prescribing as a predictor for long-term mortality after hip fracture. Gerontology. 2014;60(2):114–22. https://doi.org/10.1159/000355327.PubMedCrossRef

70.

Tosato M, Landi F, Martone AM, et al. Potentially inappropriate drug use among hospitalised older adults: results from the CRIME study. Age Ageing. 2014;43(6):767–73. https://doi.org/10.1093/ageing/afu029.PubMedCrossRef

71.

Cahir C, Bennett K, Teljeur C, et al. Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. Br J Clin Pharmacol. 2013;77(1):201–10. https://doi.org/10.1111/bcp.12161.PubMedCentralCrossRef

72.

Maggiore RJ, Dale W, Gross CP, et al. Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J Am Geriatr Soc. 2014;62(8):1505–12. https://doi.org/10.1111/jgs.12942.PubMedPubMedCentralCrossRef

73.

Price SD, Holman CD, Sanfilippo FM, et al. Impact of specific Beers criteria medications on associations between drug exposure and unplanned hospitalisation in elderly patients taking high-risk drugs: a case-time-control study in Western Australia. Drugs Aging. 2014;31(4):311–25. https://doi.org/10.1007/s40266-014-0164-6.PubMedCrossRef

74.

Onder G, Landi F, Liperoti R, et al. Impact of inappropriate drug use among hospitalized older adults. Eur J Clin Pharmacol. 2005;61(5–6):453–9. https://doi.org/10.1007/s00228-005-0928-3.PubMedCrossRef

75.

Fick DM, Mion LC, Beers MH, et al. Health outcomes associated with potentially inappropriate medication use in older adults. Res Nurs Health. 2008;31(1):42–51. https://doi.org/10.1002/nur.20232.PubMedPubMedCentralCrossRef

76.

Stockl KM, Le L, Zhang S, et al. Clinical and economic outcomes associated with potentially inappropriate prescribing in the elderly. Am J Manag Care. 2010;16(1):e1–10.PubMed

77.

Dedhiya SD, Hancock E, Craig BA, et al. Incident use and outcomes associated with potentially inappropriate medication use in older adults. Am J Geriatr Pharmacother. 2010;8(6):562–70. https://doi.org/10.1016/s1543-5946(10)80005-4.PubMedCrossRef

78.

Pasina L, Djade CD, Tettamanti M, et al. Prevalence of potentially inappropriate medications and risk of adverse clinical outcome in a cohort of hospitalized elderly patients: results from the REPOSI study. J Clin Pharm Ther. 2014;39(5):511–5. https://doi.org/10.1111/jcpt.12178.PubMedCrossRef

79.

Somers A, Mallet L, van der Cammen T, et al. Applicability of an adapted medication appropriateness index for detection of drug-related problems in geriatric inpatients. Am J Geriatr Pharmacother. 2012;10(2):101–9. https://doi.org/10.1016/j.amjopharm.2012.01.003.PubMedCrossRef

80.

Olsson IN, Runnamo R, Engfeldt P. Medication quality and quality of life in the elderly, a cohort study. Health Qual Life Outcomes. 2011;9:95. https://doi.org/10.1186/1477-7525-9-95.PubMedCrossRef

81.

Hanlon JT, Sloane RJ, Pieper CF, et al. Association of adverse drug reactions with drug-drug and drug-disease interactions in frail older outpatients. Age Ageing. 2011;40(2):274–7. https://doi.org/10.1093/ageing/afq158.PubMedCrossRef

82.

Lund BC, Carnahan RM, Egge JA, et al. Inappropriate prescribing predicts adverse drug events in older adults. Ann Pharmacother. 2010;44(6):957–63. https://doi.org/10.1345/aph.1M65710.1345/aph.1M657A.PubMedCrossRef

83.

Wimmer BC, Dent E, Visvanathan R, et al. Polypharmacy and medication regimen complexity as factors associated with hospital discharge destination among older people: a prospective cohort study. Drugs Aging. 2014;31(8):623–30. https://doi.org/10.1007/s40266-014-0185-1.PubMedCrossRef

84.

Wimmer BC, Dent E, Bell JS, et al. Medication regimen complexity and unplanned hospital readmissions in older people. Ann Pharmacother. 2014;48(9):1120–8. https://doi.org/10.1177/1060028014537469.PubMedCrossRef

85.

Peklar J, O’Halloran AM, Maidment ID, et al. Sedative load and frailty among community-dwelling population aged ≥ 65 years. J Am Med Dir Assoc. 2015;16(4):282–9. https://doi.org/10.1016/j.jamda.2014.10.010.PubMedCrossRef

86.

Gnjidic D, Le Couteur DG, Hilmer SN, et al. Sedative load and functional outcomes in community-dwelling older Australian men: the CHAMP study. Fundam Clin Pharmacol. 2014;28(1):10–9. https://doi.org/10.1111/j.1472-8206.2012.01063.x.PubMedCrossRef

87.

Taipale HT, Bell JS, Soini H, et al. Sedative load and mortality among residents of long-term care facilities: a prospective cohort study. Drugs Aging. 2009;26(10):871–81. https://doi.org/10.2165/11317080-000000000-00000.PubMedCrossRef

88.

Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59(8):1477–83. https://doi.org/10.1111/j.1532-5415.2011.03491.x.PubMedCrossRef

89.

Pasina L, Djade CD, Lucca U, et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging. 2013;30(2):103–12. https://doi.org/10.1007/s40266-012-0044-x.PubMedCrossRef

90.

Lampela P, Lavikainen P, Garcia-Horsman JA, et al. Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study. Drugs Aging. 2013;30(5):321–30. https://doi.org/10.1007/s40266-013-0063-2.PubMedCrossRef

91.

Zimmerman KM, Salow M, Skarf LM, et al. Increasing anticholinergic burden and delirium in palliative care inpatients. Palliat Med. 2014;28(4):335–41. https://doi.org/10.1177/0269216314522105.PubMedCrossRef

92.

Kersten H, Molden E, Tolo IK, et al. Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2013;68(3):271–8. https://doi.org/10.1093/gerona/gls176.PubMedCrossRef

93.

Lowry E, Woodman RJ, Soiza RL, et al. Associations between the anticholinergic risk scale score and physical function: potential implications for adverse outcomes in older hospitalized patients. J Am Med Dir Assoc. 2011;12(8):565–72. https://doi.org/10.1016/j.jamda.2011.03.006.PubMedCrossRef

94.

Koshoedo S, Soiza RL, Purkayastha R, et al. Anticholinergic drugs and functional outcomes in older patients undergoing orthopaedic rehabilitation. Am J Geriatr Pharmacother. 2012;10(4):251–7. https://doi.org/10.1016/j.amjopharm.2012.06.003.PubMedCrossRef

95.

Kersten H, Molden E, Willumsen T, et al. Higher anticholinergic drug scale (ADS) scores are associated with peripheral but not cognitive markers of cholinergic blockade. Cross sectional data from Norwegian nursing homes. Br J Clin Pharmacol. 2013;75(3):842–9. https://doi.org/10.1111/j.1365-2125.2012.04411.x.PubMedPubMedCentralCrossRef

96.

Marcum ZA, Wirtz HS, Pettinger M, et al. Anticholinergic medication use and falls in postmenopausal women: Findings from the Women’s Health Initiative cohort study. BMC Geriatr. 2016;16:76. https://doi.org/10.1186/s12877-016-0251-0.PubMedPubMedCentralCrossRef

97.

Kumpula EK, Bell JS, Soini H, et al. Anticholinergic drug use and mortality among residents of long-term care facilities: a prospective cohort study. J Clin Pharmacol. 2011;51(2):256–63. https://doi.org/10.1177/0091270010368410.PubMedCrossRef

98.

Mubang RN, Stoltzfus JC, Cohen MS, et al. Comorbidity-polypharmacy score as predictor of outcomes in older trauma patients: a retrospective validation study. World J Surg. 2015;39(8):2068–75. https://doi.org/10.1007/s00268-015-3041-5.PubMedCrossRef

99.

Evans DC, Cook CH, Christy JM, et al. Comorbidity-polypharmacy scoring facilitates outcome prediction in older trauma patients. J Am Geriatr Soc. 2012;60(8):1465–70. https://doi.org/10.1111/j.1532-5415.2012.04075.x.PubMedCrossRef

100.

Justiniano CF, Coffey RA, Evans DC, et al. Comorbidity-polypharmacy score predicts in-hospital complications and the need for discharge to extended care facility in older burn patients. J Surg Res. 2014;36(1):193–6. https://doi.org/10.1097/bcr.0000000000000094.

101.

Mangoni AA, van Munster BC, Woodman RJ, et al. Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures. Am J Geriatr Psychiatry. 2013;21(8):785–93. https://doi.org/10.1016/j.jagp.2013.01.012.PubMedCrossRef

102.

Bostock CV, Soiza RL, Mangoni AA. Associations between different measures of anticholinergic drug exposure and Barthel Index in older hospitalized patients. Ther Adv Drug Saf. 2013;4(6):235–45. https://doi.org/10.1177/2042098613500689.PubMedPubMedCentralCrossRef

103.

Dispennette R, Elliott D, Nguyen L, et al. Drug burden index score and anticholinergic risk scale as predictors of readmission to the hospital. Consul Pharm. 2014;29(3):158–68. https://doi.org/10.4140/TCP.n.2014.158.CrossRef

104.

Hilmer SN, Mager DE, Simonsick EM, et al. Drug burden index score and functional decline in older people. Am J Med. 2009;122(12):1142–9. https://doi.org/10.1016/j.amjmed.2009.02.021.PubMedPubMedCentralCrossRef

105.

Gnjidic D, Cumming RG, Le Couteur DG, et al. Drug burden index and physical function in older Australian men. Br J Clin Pharmacol. 2009;68(1):97–105. https://doi.org/10.1111/j.1365-2125.2009.03411.x.PubMedPubMedCentralCrossRef

106.

Gnjidic D, Bell JS, Hilmer SN, et al. Drug burden index associated with function in community-dwelling older people in Finland: a cross-sectional study. Ann Med. 2012;44(5):458–67. https://doi.org/10.3109/07853890.2011.573499.PubMedCrossRef

107.

Wilson NM, Hilmer SN, March LM, et al. Associations between drug burden index and mortality in older people in residential aged care facilities. Drugs Aging. 2012;29(2):157–65. https://doi.org/10.2165/11598570-000000000-00000.PubMedCrossRef

108.

Wilson NM, Hilmer SN, March LM, et al. Associations between drug burden index and physical function in older people in residential aged care facilities. Age Ageing. 2010;39(4):503–7. https://doi.org/10.1093/ageing/afq053.PubMedCrossRef

109.

Wilson NM, Hilmer SN, March LM, et al. Associations between drug burden index and falls in older people in residential aged care. J Am Geriatr Soc. 2011;59(5):875–80. https://doi.org/10.1111/j.1532-5415.2011.03386.x.PubMedCrossRef

110.

Best O, Gnjidic D, Hilmer SN, et al. Investigating polypharmacy and drug burden index in hospitalised older people. Intern Med J. 2013;43(8):912–8. https://doi.org/10.1111/imj.12203.PubMedCrossRef

111.

Dauphinot V, Faure R, Omrani S, et al. Exposure to anticholinergic and sedative drugs, risk of falls, and mortality: an elderly inpatient, multicenter cohort. J Clin Psychopharmacol. 2014;34(5):565–70. https://doi.org/10.1097/jcp.0000000000000195.PubMedCrossRef

112.

Lonnroos E, Gnjidic D, Hilmer SN, et al. Drug burden index and hospitalization among community-dwelling older people. Drugs Aging. 2012;29(5):395–404. https://doi.org/10.2165/11631420-000000000-00000.PubMedCrossRef

113.

Lowry E, Woodman RJ, Soiza RL, et al. Drug burden index, physical function, and adverse outcomes in older hospitalized patients. J Clin Pharmacol. 2012;52(10):1584–91. https://doi.org/10.1177/0091270011421489.PubMedCrossRef

114.

Gnjidic D, Hilmer SN, Blyth FM, et al. High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther. 2012;91(3):521–8. https://doi.org/10.1038/clpt.2011.258.PubMedCrossRef

115.

Kaufmann CP, Tremp R, Hersberger KE, et al. Inappropriate prescribing: a systematic overview of published assessment tools. Eur J Clin Pharmacol. 2014;70(1):1–11. https://doi.org/10.1007/s00228-013-1575-8.PubMedCrossRef

116.

Villalba-Moreno AM, Alfaro-Lara ER, Perez-Guerrero MC, et al. Systematic review on the use of anticholinergic scales in poly pathological patients. Arch Gerontol Geriatr. 2016;62:1–8. https://doi.org/10.1016/j.archger.2015.10.002.PubMedCrossRef

117.

Wang KCM, Veluswamy R. Evidence-based strategies to reduce polypharmacy: a review. OA Elderly Med. 2013;1:6.

118.

Levy HB, Marcus EL, Christen C. Beyond the Beers criteria: a comparative overview of explicit criteria. Ann Pharmacother. 2010;44(12):1968–75. https://doi.org/10.1345/aph.1P426.PubMedCrossRef

119.

O’Mahony D, Gallagher PF. Inappropriate prescribing in the older population: need for new criteria. Age Ageing. 2008;37(2):138–41. https://doi.org/10.1093/ageing/afm189.PubMedCrossRef

120.

Taipale HT, Hartikainen S, Bell JS. A comparison of four methods to quantify the cumulative effect of taking multiple drugs with sedative properties. Am J Geriatr Pharmacother. 2010;8(5):460–71. https://doi.org/10.1016/j.amjopharm.2010.10.004.PubMedCrossRef

121.

Cadogan CA, Ryan C, Hughes CM. Appropriate polypharmacy and medicine safety: when many is not too many. Drug Saf. 2016;39(2):109–16. https://doi.org/10.1007/s40264-015-0378-5.PubMedCrossRef

122.

Hill-Taylor B, Walsh KA, Stewart S, et al. Effectiveness of the STOPP/START (Screening Tool of Older persons’ Potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria: systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther. 2016;41(2):158–69. https://doi.org/10.1111/jcpt.12372.PubMedCrossRef

123.

Lund BC, Steinman MA, Chrischilles EA, et al. Beers criteria as a proxy for inappropriate prescribing of other medications among older adults. Ann Pharmacother. 2011;45(11):1363–70. https://doi.org/10.1345/aph.1Q361.PubMedPubMedCentralCrossRef

124.

Australian Medicines Handbook Pty Ltd. Prescribing for the elderly. In: The Australian Medicines Handbook. Australian Medicines Handbook Pty Ltd. 2017. https://amhonline-amh-net-au.access.library.unisa.edu.au/guides/guide-elderly. Accessed 10 May 2017.

125.

Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–34. https://doi.org/10.1001/jamainternmed.2015.0324.PubMedCrossRef

Title: Tools for Assessment of the Appropriateness of Prescribing and Association with Patient-Related Outcomes: A Systematic Review
Authors: Nashwa Masnoon
Sepehr Shakib
Lisa Kalisch-Ellett
Gillian E. Caughey
Publication date: 01-01-2018
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 1/2018
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-018-0516-8

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Treatment of Older Patients with Acute Lymphoblastic Leukaemia

Drug Burden and its Association with Falls Among Older Adults in New Zealand: A National Population Cross-Sectional Study

Brain Over Bladder: A Systematic Review of Dual Cholinesterase Inhibitor and Urinary Anticholinergic Use

Associations between the Drug Burden Index, Potentially Inappropriate Medications and Quality of Life in Residential Aged Care

Incontinence-Associated Dermatitis: Pathogenesis, Contributing Factors, Prevention and Management Options

The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage